MDX-060 in Patients With Relapsed or Refractory Classic Systemic or Primary Cutaneous Anaplastic Large Cell Lymphoma
Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This study is an open-label, fixed-dose, multicenter study of MDX-060 in patients with ALCL
who have relapsed or refractory disease. There will be 3 phases of this study: Induction,
Maintenance, and Follow-up. Patients will be required to attend all protocol-required visits
in the 4-week Induction Phase, in which administration of MDX-060 will occur, as well as
other testing. Patients who complete the Induction Phase may be eligible for additional
MDX-060 treatment ever 2 months for 1 year in the Maintenance Phase. Patients who complete
the Maintenance Phase with a response of stable disease or better will be followed every 2
months for 1 year or until disease progression. The purpose of this study is to determine
objective response rate at Day 50 in patients with relapsed or refractory classic systemic
ALCL or primary cutaneous ALCL treated with MDX-060. Other objectives will be evaluated.